Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT).
Shamshad F, Kenchaiah S, Finn PV, Soler-Soler J, McMurray JJ, Velazquez EJ, Maggioni AP, Califf RM, Swedberg K, Kober L, Belenkov Y, Varshavsky S, Pfeffer MA, Solomon SD; VALsartan In Acute myocardial iNfarcTion (VALIANT) Trial Investigators. Shamshad F, et al. Among authors: mcmurray jj. Am Heart J. 2010 Jul;160(1):145-51. doi: 10.1016/j.ahj.2010.02.037. Am Heart J. 2010. PMID: 20598985 Clinical Trial.
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry.
Shah MR, Granger CB, Bart BA, McMurray JJ, Petrie MC, Michelson EL, Tudor GE, Swedberg K, Stevenson LW, Califf RM, Pfeffer MA. Shah MR, et al. Among authors: mcmurray jj. Am J Med. 2000 Oct 15;109(6):489-92. doi: 10.1016/s0002-9343(00)00529-5. Am J Med. 2000. PMID: 11042239 No abstract available.
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.
Janardhanan R, Kenchaiah S, Velazquez EJ, Park Y, McMurray JJ, Weaver WD, Finn PV, White HD, Marin-Neto JA, O'Connor C, Pfeffer MA, Califf RM, Solomon SD; VALIANT Investigators. Janardhanan R, et al. Among authors: mcmurray jj. Am Heart J. 2006 Jul;152(1):183-9. doi: 10.1016/j.ahj.2005.11.013. Am Heart J. 2006. PMID: 16824854
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S; CHARM Investigators. Ducharme A, et al. Among authors: mcmurray jj. Am Heart J. 2006 Jul;152(1):86-92. Am Heart J. 2006. PMID: 16838426
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators. Solomon SD, et al. Among authors: mcmurray jj. Circulation. 2006 Sep 5;114(10):1028-35. doi: 10.1161/CIRCULATIONAHA.106.636746. Circulation. 2006. PMID: 16943394 Clinical Trial.
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
Lewis EF, Lamas GA, O'Meara E, Granger CB, Dunlap ME, McKelvie RS, Probstfield JL, Young JB, Michelson EL, Halling K, Carlsson J, Olofsson B, McMurray JJ, Yusuf S, Swedberg K, Pfeffer MA; CHARM Investigators. Lewis EF, et al. Among authors: mcmurray jj. Eur J Heart Fail. 2007 Jan;9(1):83-91. doi: 10.1016/j.ejheart.2006.10.012. Epub 2006 Dec 21. Eur J Heart Fail. 2007. PMID: 17188020 Free article.
1,437 results